at 1727

Bimolane is a topoisomerase II inhibitor.

VK-1727, a selective small molecule inhibitor of EBNA1, reduces the DNA binding activity of EBNA1 while simultaneously restricting the proliferation and metabolic activity of EBV-positive cells, it does so without influencing the viability of EBV-negative cells, thereby demonstrating specificity. VK-1727 is primarily employed in researchs that focus on multiple sclerosis, in which it serves as a tool compound to interrogate EBNA1-mediated mechanisms in disease-related processes.

CDK8/19-IN-51 is an orally active and highly effective dual inhibitor of CDK8 and CDK19, with anticancer activity. Its IC50 values for CDK8 and CDK19 are 5.1 nM and 5.6 nM, respectively. It is used in studies of colorectal and gastric cancers.